Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 3548936, 3 pages
https://doi.org/10.1155/2017/3548936
Case Report

Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia

1Cancer Molecular Diagnostics, St. James’s Hospital, Dublin 8, Ireland
2Department of Haematology, Mater Misericordiae University Hospital, Dublin 7, Ireland

Correspondence should be addressed to Stephen E. Langabeer; ei.semajts@reebagnals

Received 22 September 2017; Accepted 16 November 2017; Published 11 December 2017

Academic Editor: Takashi Sonoki

Copyright © 2017 Mireille Crampe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Hochhaus, R. A. Larson, F. Guilhot et al., “Long-term outcomes of imatinib treatment for chronic myeloid leukemia,” New England Journal of Medicine, vol. 376, no. 10, pp. 917–927, 2017. View at Publisher · View at Google Scholar
  2. E. Jabbour, H. Kantarjian, and J. Cortes, “Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm,” Clinical Lymphoma Myeloma & Leukemia, vol. 15, no. 6, pp. 323–334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Soverini, A. Hochhaus, F. E. Nicolini et al., “BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet,” Blood, vol. 118, no. 5, pp. 1208–1215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Branford, Z. Rudzki, S. Walsh et al., “High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance,” Blood, vol. 99, no. 9, pp. 3472–3475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Branford, Z. Rudzki, S. Walsh et al., “Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis,” Blood, vol. 102, no. 1, pp. 276–283, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Soverini, G. Martinelli, G. Rosti et al., “ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4100–4109, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Hess, R. G. Meyer, B. Schuch, K. Bechtold, I. El-Kholy, and C. Huber, “Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up,” American Journal of Hematology, vol. 83, no. 3, pp. 178–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. L. McCarron, L. M. O’Connor, S. E. Langabeer, and E. Conneally, “BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients,” Genetic Testing and Molecular Biomarkers, vol. 17, no. 2, pp. 170–173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Redaelli, L. Mologni, R. Rostagno et al., “Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors,” American Journal of Hematology, vol. 87, no. 11, pp. E125–E128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. K. E. Flynn and E. Atallah, “Quality of life and long-term therapy in patients with chronic myeloid leukemia,” Current Hematology Malignancy Reports, vol. 11, no. 2, pp. 80–85, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Baccarani, M. W. Deininger, G. Rosti et al., “European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013,” Blood, vol. 122, no. 6, pp. 872–884, 2013. View at Publisher · View at Google Scholar · View at Scopus